-
8-Methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
-
BD16542313-67-798%
-
¥882.0100mg
-
(E)-2-((4,5-Dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid
-
BD755792136164-66-498%
-
¥463.05mg
-
1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
-
BD595653719-45-797%
-
¥2942.0100g
-
Pnri-299
-
BD630761550368-41-799+%
-
¥5525.05mg
-
Methyllinderone
-
BD2358643984-73-498+%
-
¥1281.05mg
-
Timolumab
-
BD016542571073538-99-495%
-
¥
-
SSAO/VAP-1 inhibitor 1
-
BD015305532647975-06-098%
-
¥
-
1-[(2-Chlorophenyl)methyl]-5'-phenyl-1,2-dihydro-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2-one
-
BD01163752331458-02-798%
-
¥2286.025mg
-
rel-5-((1S,3aR,4R,6aR)-4-(3,4-Dimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan-1-yl)benzo[d][1,3]dioxole
-
BD12998731008-19-297%
-
¥942.025mg
-
1-((5-Methoxy-2-(thiophen-2-yl)quinazolin-4-yl)amino)-3-methyl-1H-pyrrole-2,5-dione
-
BD01127990219773-55-498%
-
¥
-
(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-((3-hydroxyphenyl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate
-
BD015087981221412-23-295%
-
¥
-
(2E,4E,6Z,8E)-3-Methyl-7-(p-tolyl)-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
-
BD292786160162-42-598+%
-
¥2617.010mg
-
INI-43
-
BD01186459881046-01-197%
-
¥17537.0100mg
-
Fas C-Terminal Tripeptide
-
BD112621189109-90-898%
-
¥
-
Glucocorticoid receptor modulator 1
-
BD018188552868357-11-198%
-
¥
-
(S)-(1R,2R,3R,3aS,3a1S,4R,6aR,7aS,11S,11aS,11bR)-1,2,11-Trihydroxy-3,8,11a-trimethyl-5,10-dioxo-2,3,3a,4,5,6a,7,7a,10,11,11a,11b-dodecahydro-1H-1,3a1-(epoxymethano)dibenzo[de,g]chromen-4-yl 2-hydroxy-2-methylbutanoate
-
BD012784191259-86-597%
-
¥
-
Torilin
-
BD29870813018-10-598+%
-
¥2125.05mg
-
Ganoderic acid H
-
BD63749198665-19-197%
-
¥